Submit a manuscript Sign up for article alerts Contact us Support

RSS

Latest comments

Does Irisin Really Exist in Human Circulation ? JiaQi Chen, Shen Qu*Corresponding author: Shen Qu qushencn@hotmail.com (Jiaqi Chen, 13 May 2015)

Recently, Elke Albrecht et al. [1] questioned about the existence of circulating irisin in human by testing the accuracy of four polyclonal antibodies used in commercial ELISA kits, using Western Blot. The researchers used recombinant non-glycosylated and glycosylated irisin (molecular weights are ~13kDa and ~20kDa, respectively) as positive standards. They found that the antibodies could only detect the recombinant irisin added in PBS, but no band was found at the same position in murine or in human samples. Furthermore, the antibodies were found to have prominent cross-reaction with unspecific proteins, and the bands of similar molecular weight of recombinant irisin at ~16kDa and ~25kDa were further examined by mass spectrometric analysis and proved not to be... read full comment

Comment on: Chen et al. Lipids in Health and Disease, 14:2

Revise and correct for AI distributionin in Table 4 (Nain-Feng Chu, 21 April 2015)

There are some typos in the AI distribution of Table 4.
The AI distribution of AGE less and equal 2.0 and greater than 2.0 subgroups are
AI: 0-4: 44 (50.0%) vs. 5 (7.8%) for male and 49 (46.7%) vs. 21 (16.9%) for female;
AI: 5-8: 37 (42.0%) vs. 39 (60.9%) for male and 47 (44.8%) vs. 67 (54.0%) for female;
AI: 9-12: 7 (8.0%) vs. 20 (31.3%) for male and 9 (8.5%) vs. 36 (29.1%) for female. read full comment

Comment on: Chang et al. Lipids in Health and Disease, 10:228

How Come EPA+DHA Improved but Insulin Action Didn't? (stephen phinney, 09 January 2015)

The data in this report are very interesting, but the authors¿ interpretation is puzzling. It appears that the authors have decided a priori that the only important fatty acids in muscle PL vis-à-vis insulin action are EPA and DHA. Thus they proudly report that DHA increases from 2.08 to 2.81 wt% and EPA from 0.86 to 1.13 across the 24-week ¿maintenance¿ period (which actually resulted in a significant loss of fat mass due to Orlistat Rx). However in this same time period, there were no commensurate improvements in serum insulin, glucose, or HOMA-IR. In fact, all three of these parameters of insulin action got worse (albeit non-significantly) as EPA and DHA contents in the membrane PL rose significantly.... read full comment

Comment on: Haugaard et al. Lipids in Health and Disease, 8:34

DHA and DPA levels? (Lars I. Hellgren, 09 January 2015)

I wonder why data on DHA and DPA is lacking in this manuscript. I find it very peculiar to discuss relation between certain phenotypic features (i e metabolic syndrome) and PUFA composition, without taking these two very important n-3 PUFA into account
Best regards
Lars read full comment

Comment on: Novgorodtseva et al. Lipids in Health and Disease, 10:82

Fenofibrate Contraindications in United States (Jeffrey Minniti, 09 January 2015)

In the US, severe renal disease is an absolute contraindication to the use of fenofibrate. This advisory is supported by the maker of Tricor and Trilipix (Abott), The National Kidney Foundation, and the National Lipid Association. The drug is significantly excreted by the kidneys, and is negligibly removed by hemodialysis. This study's duration was a mere 63 days. Toxic accumulation of fenofibrate has been documented in this patient population with more prolonged regimens. Many didn't become symptomatic until several months (or years) had passed. Neuromyopathy is not uncommon in this clinical setting. Gemfibrozil is the only fibrate that is OK'd for use in hemodialysis in the US. Even then, it requires regular monitoring of Creatine Kinase levels......and vigilance by the... read full comment

Comment on: Makówka et al. Lipids in Health and Disease, 11:47

Thymoquinone Toxicity (MAJED MAK, 09 January 2015)

I have two comments about this... read full comment

Comment on: Badr et al. Lipids in Health and Disease, 12:37

Clarification from the authors (Lucy Abel, 26 February 2014)

The two articles, published by my group, include the data of plasma laboratory tests, which were shown in Fig.3 (pubished above) and Table 2 (published in Redox Biology: Cui Y, Wang Q, Li X, Zhang X. Experimental nonalcoholic fatty liver disease in mice leads to cytochrome p450 2a5 upregulation through nuclear factor erythroid 2-like 2 translocation. Redox Biol. 2013 Aug 24;1(1):433-40.) respectively. The two data were similar, but they were from the different samples of mice. read full comment

Comment on: Wang et al. Lipids in Health and Disease, 12:165

Renal Dosing (Jeffrey Minniti, 21 October 2013)

In the US, fenofibrate is contraindicated in severe renal failure (including those on chronic dialysis). It has significant renal excretion, and is not removed by hemodialysis. Those with negligible creatinine clearances would be at risk for cumulative toxicity. Neuromyopathies (including rhabdomyolysis) have been documented in this patient population. Co-administered drugs such as colchicine can potentiate this effect. read full comment

Comment on: Makówka et al. Lipids in Health and Disease, 11:47

CEO-PhD (Halina Malina, 05 January 2012)

It is a model of anesthetic product... read full comment

Comment on: Dontas et al. Lipids in Health and Disease, 10:139

Table 6 Diastolic Blood Pressure error (Gordon Francis, 05 January 2012)

Please note the Diastolic Blood Pressure readings and p value in Table 6 had an error that was not noted in proofing of the manuscript. The correct values are:
Diastolic blood pressure
Initial visit 78.92 ± 11.36 mm Hg
Latest visit 77.92 ± 10.63 mm Hg
p=0.198

Gordon Francis
Corresponding Author read full comment

Comment on: Sandhu et al. Lipids in Health and Disease, 10:157

Typographical error in Methods (Elisardo C Vasquez, 04 July 2011)

After publication we, the authors, noticed a typographical error in the article. In the methods section, ¿4.7 MgSO, 1.17 H2O¿ should be ¿4.7 MgSO4¿7H2O¿. We apologise for any inconvenience caused to the reader. read full comment

Comment on: Pereira et al. Lipids in Health and Disease, 10:80

Editing comment (Zeinab Ghazanfari, 21 August 2010)

After the B.4.1 paragraph should be a point. read full comment

Comment on: Ghazanfari et al. Lipids in Health and Disease, 9:83

Membrane cholesterol, lactic acid and cancer (dhastagir sheriff, 21 August 2010)

It is very interesting to note that lactic acid producing bacteria reduce plasma cholesterol and possibly influence membrane cholesterol in cancer patients.One need to understand that there is always a thin line that divides beneficial as well as harmful effects. One must remember that lactic acidosis is an end stage complication of patients with metastases in the liver(1). Altering membrane cholesterol may affect membrane signaling pathways so vital for maintaining cell growth and regulation. (2). Therefore, one must be cautious in extrapolating experimental results to say human cancer biology and therapy.
References:
1. D. S. Sheriff Lactic acidosis and small cell carcinoma of the lung. Postgrad Med J 1986;62:297-298
2. Xu Chen and Marilyn D. Resh. Cholesterol Depletion... read full comment

Comment on: Lee et al. Lipids in Health and Disease, 8:21

Change of the first name of Author 3 (Satoshi Yoshida, 04 August 2010)

Please correct the first name of Author 3 from "Syu" to "Shu". Basically both are OK for pronunciation of the corresponding Japanese word, but this change to "Shu" is a request from the author 3. read full comment

Comment on: Yoshida et al. Lipids in Health and Disease, 8:28

No comments (Ruxing Wang, 02 July 2010)

No comments about MS: 1020865855363367 read full comment

Comment on: Wang et al. Lipids in Health and Disease, 9:39

Change a comma in table 2 by a point (JOSE ALFREDO MARTINEZ, 22 June 2010)

Dear Mrs/Mr:
In table 2, in "lactate" parameter (HFS column) it says 22,4±2.9 and should say 22.4±2.9
I would gratefull if you could change this error.
Best wishes,
Almudena Lomba read full comment

Comment on: Lomba et al. Lipids in Health and Disease, 9:60

question? (Cheryl Jackson, 12 June 2010)

I would like to know where I could order lepticore.

Thank you for your help! read full comment

Comment on: Kuate et al. Lipids in Health and Disease, 9:20

Reference (Demosthenes Panagiotakos, 29 April 2010)

Until this issue completely resolved by the Publisher, and in order to avoid any misunderstanding it should be clarified to the reader that Ref #12 (ie., Katsouyanni et al. Int J Epidemiol. 1997;26:S118–S127), does not refer to the FFQ used in this work. read full comment

Comment on: Polychronopoulos et al. Lipids in Health and Disease, 4:17

Paramount Inherited Functional Mitochondrial Cytopathy, Pre-Metabolic and Metabolic Syndrome are based on. (Sergio Stagnaro, 04 October 2008)

Sirs,this paper is really intriguing and interesting. However, in Primary Prevention as well as early bedside diagnosis of Metabolic Syndrome, physicians have necessarily to know Biophysical-Semeiotic Constitutions, fundamental ground of Single Patient Based Medicine, which fortunately completes EBM! (1, 2). Really, the constitutions exist and are based on inherited mitochondrial functional cytopathy, I discovered and described - for the first time - about 30 years ago, and termed as Congenital Acidosic Enzyme Metabolic Histangiopathy (1-15). Notoriously, Metabolic Syndrome (i.e., all its components) is preceded by the related biophysical-semeiotic constitutions, their corresponding inherited Real Risk, and then by Biophysical Semeiotic Pre-Metabolic Syndrome (See... read full comment

Comment on: Rubin et al. Lipids in Health and Disease, 7:32

Pre-Metabolic and Metabolic Syndrome are based on Inherited Mitochondrial Cytopathy. (Sergio Stagnaro, 04 October 2008)

Sirs,I find this paper really interesting and useful in preventing rather than recognizing metabolic syndrome. However, in Primary Prevention as well as early bedside diagnosis of Metabolic Syndrome, physicians have at the best to know Biophysical-Semeiotic Constitutions, fundamental ground of Single Patient Based Medicine, which fortunately completes EBM! (1, 2). Really, these constitutions exist and are based on inherited mitochondrial functional cytopathy, I discovered and described - for the first time - about 30 years ago, and termed as Congenital Acidosic Enzyme Metabolic Histangiopathy (1-15). Notoriously, Metabolic Syndrome (i.e., all its components) is preceded by the related biophysical-semeiotic constitutions, their corresponding inherited Real Risk, and then by Biophysical... read full comment

Comment on: Rubin et al. Lipids in Health and Disease, 7:32

Bedside Recognizing CAD Inherited Real Risk and silent CAD with Biophysical Semeiotics. (Sergio Stagnaro, 29 May 2008)

Editors,nowadays physicians could be able to recognize CLINICALLY, quickly and easily, coronary artery disease, even in earliest stage, i.e., INHERITED Real Risk of CAD, and obviously overt CAD, even silent, by means of Biophysical Semeiotics (1-9) (See www.semeioticabiofisica.it, Practical Applications). , Thanks to a few open-minded, farsighted physicians and "peer-reviewers" , bedside methods reliable in diagnosing CAD real risk is now-a-days an efficacious clinical tool, which proved to be of paramount importance in CAD Primary Prevention (1-9).As a matter of facts, not all hypertensive or diabetic or dyslipidaemic patients are neither suffering of ouvert CAD, nor at real risk of CAD (4, 8). A large number of well-known randomized trials report the benefits of both diuretics and... read full comment

Comment on: Das Lipids in Health and Disease, 7:19

Cissus quadrangularis, fat loss and competing interests (Anssi Manninen, 07 May 2008)

The lead author of this study has a patent on Cissus quadrangularis as a fat loss agent. A competing interest exists when professional judgement concerning a primary interest may be influenced by a secondary interest (e.g., financial gain). While there is nothing inherently unethical about a competing interest, they should be acknowledged and openly stated.Anssi ManninenManninen Nutraceuticals OyOulu, Finland read full comment

Comment on: Oben et al. Lipids in Health and Disease, 7:12

Question from a non-professional (Susan Williams, 02 February 2008)

Is there any real help available at this time for those people with high cholesterol who clearly cannot tolerate statins-- or are they doomed ? Thank you. Goldysue@mindspring.com read full comment

Comment on: Oh et al. Lipids in Health and Disease, 6:7

Pivotal Role of Liver PPARs Activity Bed-side Evaluation in Monitoring glucidic and lipidic Metabolism. (Sergio Stagnaro, 02 June 2007)

Sirs, in my view, in the primary prevention of all components of metabolic syndrome, and particularly hyperinsulinaemia-insulinresistance, IGT, and type 2 diabetes, first of all, doctors have to recognize on very large scale Pre-Metabolic syndrome, classic and variant, I described earlier (See web site www.semeioticabiofisica.it/microangiologia.it, Pre-Metabolic Syndrome, URL http://www.semeioticabiofisica.it/microangiologia/Documenti/Eng/Pre-metabolic%20syndrome%20engl.doc After that, doctors have to monitor at the bed-side pre-metabolic syndrome initial evolution to metabolic syndrome, since the well-known diabetes complications begin notoriously years or decades before diabetes onset. Among a lot of biophysical-semeiotic methods, different in technical difficulty, but similarly reliable... read full comment

Comment on: Rao et al. Lipids in Health and Disease, 6:12

Nice (Ferdinand Novak, 02 August 2006)

Nice, comprehensive author`s opinion.But, the principal question is - do we need lab entity we cannot in daily practice measure valid ? read full comment

Comment on: Gasko Lipids in Health and Disease, 5:18